Apollo Hospitals Share Price in Focus; Reports Q2FY26 Results with 26% Rise in Profit

Apollo Hospitals Enterprise Limited reported financial results for the quarter ended September 2025. 

Apollo Hospitals Q2FY26 Results

Consolidated revenues rose 13% year-on-year to ₹6,304 crore, compared to ₹5,589 crore in Q2FY25. The company’s growth was driven by continued demand across hospital, pharmacy, and digital health segments.

Healthy EBITDA and Profit Margins

Consolidated EBITDA grew 15% YoY to ₹941 crore in Q2FY26, up from ₹816 crore in the same period last year. This performance includes Apollo 24/7 costs of ₹126 crore, which also covers a ₹32 crore non-cash ESOP charge. 

Profit after tax (PAT) rose sharply by 26% YoY to ₹477 crore, compared to ₹379 crore in Q2FY25. The diluted earnings per share (EPS) for the quarter stood at ₹33.19, reflecting improved profitability and operational efficiency.

H1FY26 Financial Performance

For the first half of FY26, Apollo Hospitals achieved consolidated revenues of ₹12,146 crore, marking a 14% YoY increase. EBITDA for H1FY26 rose 20% to ₹1,793 crore, while PAT surged 33% to ₹910 crore, indicating sustained growth momentum. The diluted EPS for H1FY26 was ₹63.29 per share.

Milestones and Expansion Highlights

During the quarter, Apollo Hospitals soft launched Apollo Athenaa, Asia’s first dedicated cancer center for women, in Delhi’s Defence Colony. The company also inaugurated the Royal Mudhol Apollo Hospitals, a multi-specialty tertiary care facility in Pune. 

Over its 42-year journey, Apollo Hospitals has completed more than 51 lakh surgeries and 27,000 organ transplants. Its Chennai Children’s Hospital reached over 6,000 pediatric cardiac surgeries, while Hyderabad’s Jubilee Hills unit performed a rare Deep Brain Stimulation procedure on a 4-year-old child.

Apollo Hospitals Share Price Performance

On November 7, 2025, Apollo Hospitals share price (NSE: APOLLOHOSP) opened at ₹7,789.00, up from its previous close of ₹7,782.00. At 10:27 AM, the share price of Apollo Hospitals was trading at ₹7,711.00, down by 0.91% on the NSE.

Also Read: Apollo Hospitals to Double AI Investment Over the Next 2 to 3 Yrs!

Conclusion

Apollo Hospitals delivered another quarter, supported by revenue growth, efficiency improvements, and medical innovation. With expanding specialised facilities and consistent profitability, the company continues to strengthen its leadership in India’s healthcare sector.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.